7 Strategies to Build Credible Wound Healing Rate Benchmarks From Real-World Data

A single healing-rate figure, pulled from a pooled dataset and quoted without its definitions, rarely survives a payer, MAC, or value analysis committee review. Reviewers ask how healing was defined, which wounds were included, where care was delivered, and what happened to patients who disappeared. If the answers are vague, the number is discarded, and the product’s evidence goes with it.

Credible wound healing rate benchmarks are a methodology problem, not a data-volume problem. A larger dataset with loose definitions produces a more precise wrong answer. The seven strategies below cover definitions, stratification, setting, reference arms, missing data, confounding, and version control, and they apply equally to PMCF reporting, coverage dossiers, competitive reviews, and diligence work.

1. Fix the healing endpoint definition first

Every downstream number inherits the endpoint. If one cohort counts a wound as healed when a clinician selects “healed” in the EHR, and another requires closure confirmed at a second visit, the two rates measure different things even when the wounds are identical. Protocol-style confirmation screens out premature or reversed closures; clinician-documented status does not. The FDA’s 2006 guidance on chronic cutaneous ulcers defines complete closure as skin re-epithelialization without drainage or dressing requirements, confirmed at two consecutive visits two weeks apart, and the Wound Care Collaborative Community’s proposed addendum to that guidance reaffirms complete closure as the most meaningful endpoint.

Consider an illustration. Suppose a DFU cohort shows 58% healed under EHR “healed” status within 12 weeks, but only 51% when closure must be confirmed at a visit two weeks later. Neither figure is wrong. They answer different questions, and presenting one against a benchmark built on the other creates a gap that is purely definitional.

To put this into practice, write a benchmark specification before computing anything:

1. State the closure criterion: full epithelialization, no drainage, no dressing required, or a documented equivalent.
2. State whether a confirmation visit is required and the interval (for example, two weeks).
3. Set the time window, such as 12 or 16 weeks, and keep it fixed across comparisons.
4. Define the index date: first documented visit, first visit with the product, or start of a treatment episode.
5. List exclusions, such as wounds with fewer than two visits or non-index wounds, and state up front how amputation and death will be handled (see Strategy 5).
6. Apply the identical specification to every cohort, including reference cohorts.

The common mistake is mixing the two styles in a single comparison, typically when a real-world rate is set beside a published trial rate without checking how each defined closure. Measure two things: the share of records that meet the full endpoint definition, and the agreement rate between two competing definitions on a manually reviewed sample. A low agreement rate tells you the definition materially changes the answer and must be disclosed.

2. Stratify by wound type and baseline severity

A pooled rate is an average over wounds that heal at very different speeds. Etiology, baseline area, wound age, and grade all predict closure, so a product used on a different mix will diverge from the pooled figure for reasons unrelated to performance. A benchmark is only useful if the reader can find the stratum that resembles their population.

For example, imagine a pooled all-wound rate that looks stable across quarters while large, long-duration VLUs close at a markedly slower pace than small, recent ones. A product concentrated in the harder stratum would appear to lag the pooled number, and the pooled number would give no way to see why.

Build the strata deliberately:

• Etiology: DFU, VLU, pressure ulcer, and others reported separately.
• Baseline area bands: set cutpoints before looking at outcomes, so bands are not tuned to flatter a result.
• Wound age: for example, under versus over a set number of weeks at index.
• Grade: Wagner grade for DFUs, with an equivalent staging approach for pressure ulcers.

Then set a minimum cell size and suppress cells below it. Small cells produce swings that look like findings and invite challenge. Show confidence intervals for the cells you do publish.

The mistake to avoid is reporting a single all-wound average and comparing a product against it. Track how many strata clear the minimum sample threshold, and the spread in healing rates across strata. A wide spread is the evidence that pooling would have misled.

3. Benchmark by care setting

Hospital-based wound centers, skilled nursing facilities, and home visits differ in patient complexity, visit frequency, offloading and compression adherence, and documentation habits. Those differences affect both healing and how healing gets recorded. A benchmark that ignores setting blends three populations and three care processes into one figure.

An illustration: a product used mostly in SNFs is compared with a national rate dominated by wound-center encounters, and it appears to underperform. Some or all of that gap may reflect setting mix rather than the product. The reverse error is equally possible for a product concentrated in wound centers.

In practice, tag each encounter with its care setting at the data-model level rather than inferring it later. Build setting-specific reference rates within the strata from the previous strategy. Then compare the product’s utilization mix against the market’s, which is where Wound Care Industry Dashboard-style product utilization tracking across settings is useful: it shows where a product is actually used, which is often different from where the commercial team assumes.

The common mistake is applying a national benchmark whose setting mix differs from the product’s. Measure the between-setting variance in healing rates, and the proportion of product use in each setting. If setting variance is large and the product’s mix is skewed, a setting-matched benchmark is the only defensible comparator. State plainly where a setting has too few records to support its own reference rate.

4. Construct a like-for-like standard-of-care reference arm

A real-world product rate has no meaning without a reference. Two references are available, and they answer different questions: published control-arm rates from named trials, and a standard-care cohort built from the same real-world data. Use both, and label each clearly.

Trial control arms are collected under protocol: scheduled visits, standardized offloading or compression, strict inclusion criteria, and adjudicated closure. Real-world standard care is rarely that tightly managed. Treating a trial control rate as the real-world norm usually overstates what typical care achieves, and it makes a real-world product cohort look worse than it is.

The workflow:

1. Pull control-arm figures only from named trials, recording the source, year, population, and endpoint. Do not cite a rate you cannot trace to a publication.
2. Align your endpoint and time window to the trial’s, or document the mismatch.
3. Build a real-world standard-care cohort using the same strata, setting tags, and exclusions as the product cohort.
4. Write a short note on population differences: age, comorbidity, wound size, and how care was delivered.

Whatever trial figures you choose, verify them against the original publication before they go into a dossier; published 12- and 20-week standard-care closure rates for DFUs and VLUs vary by trial and definition, and a number recalled from memory is a liability.

The pitfall is skipping the protocol-driven-care caveat. Measure the gap between trial and real-world standard-care rates after alignment, and the size of the reference cohort. A small reference cohort should be disclosed as a limitation, not hidden.

5. Handle censoring and missing data explicitly

Real-world wound records end for many reasons that are not healing: transfer, discharge, change of facility, death, or loss to follow-up. If you drop everyone without a final visit, the remaining population skews toward patients who stayed engaged long enough to be recorded as closed, and the healed proportion rises artificially.

Take an illustration. A cohort of 1,000 wounds has 200 with no documented outcome by week 12. Dropping them and reporting healed divided by remaining 800 treats every missing patient as if they never existed. A Kaplan-Meier estimate with censoring at last known visit uses what is known about those 200 up to the point they left, and gives a more honest estimate of time to closure.

Implementation steps:

1. Define censoring events in advance: transfer, discharge for non-healing reasons, loss to follow-up after a set gap, and end of data window.
2. Decide how to treat amputation and death, and state whether they are censoring or competing events.
3. Run Kaplan-Meier curves by stratum and report median time to closure where estimable.
4. Add sensitivity analyses: a best case where censored wounds are assumed healed, and a worst case where they are assumed not healed.
5. Publish a completeness table showing records excluded and why.

The common mistake is silent exclusion followed by a simple proportion. Measure the percent censored in each stratum and the difference between the primary and sensitivity estimates. If best and worst cases diverge widely, the benchmark is fragile, and saying so builds more credibility than hiding it.

6. Adjust comparisons for confounding

Product-versus-product benchmarks in observational data suffer from channeling bias: clinicians choose advanced products for wounds that have already failed standard care, are larger, older, or more complicated. Unadjusted, those products look worse, because they were used on harder wounds.

Imagine an unadjusted comparison in which an advanced product shows a lower 12-week closure rate than standard dressings. After matching on size, duration, diabetes status, and infection, the gap narrows or reverses. The first result reflected who received the product, not what it did.

To adjust:

1. Select covariates before analysis: age, diabetes, baseline area, wound duration, infection, and care setting.
2. Build matched cohorts (propensity score or exact matching within strata) or fit a regression model.
3. Check balance with standardized mean differences and report them; a common working threshold is 0.1, though that is a convention, not a rule.
4. Run a second specification to test how sensitive the result is to model choices.
5. Disclose residual confounding, including variables you could not observe, such as vascular status or adherence.

The mistake that draws the sharpest criticism is presenting adjusted observational results as causal proof of effectiveness. Matching reduces measured confounding; it does not remove unmeasured confounding. For questions that need stronger inference, comparative effectiveness studies or prospective designs are the right tool. Measure covariate balance after matching and how far the estimate moves across model specifications.

7. Version, refresh, and deploy benchmarks deliberately

A benchmark is a dated artifact. Payment policy, coverage determinations, and product mix all shift the underlying population, and a rate computed before such a change may not describe the market after it. Reviewers will ask when the data was cut; an unanswered question undermines everything else.

An illustration of two uses: a PMCF report cites a benchmark versioned to a specific data cut, so the figure can be reproduced during an audit. A competitive review uses the same data in a different way, looking at which products share the same wound strata and settings, and finding comparators the commercial team had not considered. The first is defensive, the second offensive, and they should be labeled as such.

Create a benchmark registry with these fields:

• Benchmark name and the specification it follows.
• Owner, accountable for updates and questions.
• Version number and data cut date.
• Intended use: PMCF, coverage submission, market access, competitive intelligence, or diligence.

Re-run after major policy or dataset changes. Before citing anything about CMS skin substitute payment or MAC LCD status, check the current rules and anchor the statement with an “as of” date, since these have moved repeatedly and may move again.

The common mistake is reusing a stale benchmark after coverage or payment changes alter the product mix. Measure benchmark age in months, drift between successive versions, and the number of external submissions that cite a current version. Persistent drift is itself a finding worth explaining.

Sequencing the work: what to lock down before anything else

Start with the endpoint definition, stratification, and missing-data handling. Every later step depends on them: matching on a poorly defined endpoint only produces a more elaborate error, and a reference arm built without censoring rules inherits the same bias. These three are also the least expensive to do, since they require specification and discipline more than new data.

Once they are stable, add setting-specific references, a standard-care arm, comparative adjustment, and a refresh cadence. State the limitations of each benchmark alongside the number, because this audience trusts a figure more when its weaknesses are stated.

If you are building benchmarks for PMCF, coverage, or competitive positioning from real-world wound care data, learn more about our services.